胆固醇侧链裂解酶基因微卫星多态性与多囊卵巢综合征发病风险的关联  

Association between microsatellite polymorphism of gene CYP11a and polycystic ovary syndrome

作　　者：杨柳[1] 张磊[1] 李春辉[1] 王志萍[1] 

机构地区：[1]山东大学公共卫生学院流行病与卫生统计学系,济南250012

出　　处：《山东大学学报（医学版）》2013年第10期85-89,共5页Journal of Shandong University:Health Sciences

摘　　要：目的定量评价胆固醇侧链裂解酶基因（CYPlla）启动子（tttta）4、（tttta）6和（tttta）8微卫星多态性与多囊卵巢综合征（PCOS）发生的关联性及关联强度。方法制定原始文献的纳入和排除标准及检索策略。检索中外数据库，系统收集有关CYPlla多态性与PCOS相关性的研究报告，按照NOS标准对纳入文献进行质量评价。应用RevMan5．0软件对各文献进行异质性检验和Meta分析，得出合并后的OR值及其95％CI。结果共有8篇文献纳入Meta分析。数据合并结果显示，CYPlla启动子（tttta）。微卫星多态性与PCOS易感性之间关联性有统计学意义，OR值（95％C1）为O．75（0．59—0．95）；（tttta）。和（tttta）。微卫星多态性与PCOS易感性之间关联性无统计学意义，OR值（95％C1）分别为0．89（0．61～1．30）和0．84（0．64～1．11）。结论CYP11a启动子（tttta）。微卫星多态性是PCOS发病的保护因素，尚未见（tttta）4和（tttta）。微卫星多态性与PCOS发病风险之间的关联性。Objective To explore the association between microsatellite polymorphism （tttta） 4, （tttta） 6 and （tttta） 8 of gene CYP11 a and polycystic ovary syndrome （PCOS）. Methods Electronic search strategy was carded out among the 6 databases from home and abroad to collect qualified research papers according to the inclusion and exclusion criteria. Case-control studies on association between microsatellite polymorphism （tttta）n of gene CYP11 a and susceptibility to PCOS were collected. The combined OR values and their 95 % CI were calculated with Review Manager 5.0. Results A total of 8 eligible studies were included. Statistics of the combined data showed a significant difference between patients with PCOS carrying microsatellite polymorphism （tttta） 6 of gene CYP11 a and controls. The combined OR （95 % CI） was 0.75 （0.59-0.95）. There was no significant difference between patients with PCOS carrying microsatel- lite polymorphism （tttta）4 or （tttta）8 of gene CYPlla and controls. The combined OR（95% CI） were 0.89 （0.61- 1.30） and 0.84 （0.64-1.11 ） respectively. Conclusion The results suggest that microsatellite polymorphism （tttta） n of gene CYP11 a may not be a risk factor for PCOS, and （tttta）6 is a protective factor for PCOS.

关 键 词：多囊卵巢综合征 胆固醇侧链裂解酶基因 多态性 META分析 

分 类 号：R394.3[医药卫生—医学遗传学]